Gabapentin Tablet
Product Images NDC 71335-3057

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

A mathematical formula image depicting the creatinine clearance (CLCr) calculation. The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. The formula layout is consistent with equations for estimating renal function.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a decreasing trend in pain scores, while placebo remains relatively stable. Periods of 4-week dose titration and fixed dose are indicated.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to 7, and the y-axis shows mean pain scores from 0 to 10. Three lines compare placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show decreasing mean pain scores compared to placebo over time.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at various dosages in two studies. It shows response rates as percentages for PBO and gabapentin 3600 mg in Study 1, and PBO, gabapentin 1800 mg, and 2400 mg in Study 2. Statistically significant differences are indicated with p-values.*

FDA Label Image

Figure-4 (Figure4)

A scatter plot titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study' shows adjunctive therapy studies in patients 12 years or older with partial seizures. The x-axis represents daily gabapentin dose (600 to 1800 mg), and the y-axis shows percentage difference in responder rate (2% to 22%). Three studies labeled a, b, and c use distinct markers and indicate increasing responder rates with higher doses.*

FDA Label Image

Label (Lbl713353057)

Label for Gabapentin Tablets, USP 800 mg oral tablets, packaged as 30 tablets. The label shows the NDC 71335-3057-1 and indicates the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Ascent Pharmaceuticals, Inc. It includes storage instructions and a QR code for dosage and use information.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to side chains with amine (CH2NH2) and carboxylic acid (CH2CO2H) groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.